Toleranzia AB
Toleranzia AB was a Gothenburg-based Swedish biotech company (publ) developing a technology portfolio for the treatment of autoimmune diseases before its August 2025 statutory merger with Flerie AB, after which its operations continued as Bonsai Biotherapeutics AB.
- Company typePublic
- Founded2011
- HeadquartersGothenburg, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Toleranzia AB does
Toleranzia AB was a Swedish public limited company (publ) headquartered in Gothenburg, Sweden, operating as a clinical-stage biotechnology developer focused on treatments for autoimmune diseases. The company's offering was described as a 'technology portfolio' for autoimmune disease treatment, implying a pipeline of immunomodulatory candidates rather than a single asset — though the source data does not disclose the underlying modality (e.g., tolerogenic peptides, biologics, or cell therapy), specific product candidates, development stage, or target indications.
The organization operated with a lean structure of 1-10 employees, including a Chief Executive Officer (Charlotte Fribert), Chief Business Officer (Björn Löwenadler), Chief Financial Officer (Johanna Hultgren), and Chief Medical Officer (Vidar Wendel-Hansen). This team composition is typical of an early-stage immunology biotech, with the Chief Medical Officer role reflecting the clinical-development orientation of the business. No commercial products, pricing model, or customer relationships are disclosed.
The company's most significant corporate event was the statutory merger with Flerie AB (publ) completed on 19 August 2025, through which Toleranzia was dissolved and all its assets, liabilities, contracts, and obligations were transferred to Flerie. On the same day, the business was moved into Flerie Invest AB and then into a newly created subsidiary, Goldcup 37076 AB, which was renamed Bonsai Biotherapeutics AB on 24 September 2025. Toleranzia shareholders received 1 Flerie ordinary share for every 88 Toleranzia shares as merger consideration. As a result of this transaction, Toleranzia's autoimmune-disease business now operates as a subsidiary entity of the Stockholm-listed Flerie AB, and no revenue model, monetization mechanics, or go-to-market strategy are described in the source material.
Toleranzia AB firmographics
Firmographics- Name
- Toleranzia AB
- Legal name
- Toleranzia AB (publ)
- Website
- https://toleranzia.se
- Company type
- Public
- Founded year
- 2011
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Toleranzia AB was a Gothenburg-based Swedish biotech company (publ) developing a technology portfolio for the treatment of autoimmune diseases before its August 2025 statutory merger with Flerie AB, after which its operations continued as Bonsai Biotherapeutics AB.
- Ownership category
- akta.pro rank
Toleranzia AB industry classification
Industry- Product category
- Biotechnology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Toleranzia AB is headquartered
LocationHeadquarters
- HQ city
- Gothenburg
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Toleranzia AB business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Toleranzia AB product offering
Product offeringCore offering
Toleranzia AB is a Swedish biotechnology company that develops a technology portfolio of therapeutic candidates aimed at treating autoimmune diseases through tolerance induction. The company's pipeline is focused on modulating the immune system to address underlying disease mechanisms rather than only managing symptoms. Following the August 2025 merger with Flerie AB, the operations were transferred to a newly created subsidiary that was renamed Bonsai Biotherapeutics AB.
Product overview
No product information available. The source data is a corporate merger announcement describing the completion of the fusion between Flerie AB and Toleranzia AB on August 19, 2025, and the subsequent transfer of Toleranzia's operations to Bonsai Biotherapeutics AB. No product portfolio, services, or technology offerings are described in this source.
Differentiator
Problem solved
Functional benefit
Companies that use Toleranzia AB
Customer profileIdeal customer profiles2 records
Toleranzia AB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Toleranzia AB partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
Toleranzia AB competitors and assessment
Company assessmentDirect peers
- BioInvent International AB: Swedish clinical-stage biotech developing immune-modulating drug candidates. Directly comparable to Toleranzia as a small, Sweden-based immunology-focused biopharma pursuing novel mechanisms in immune-mediated disease.
- Hansa Biopharma AB: Swedish biopharma developing antibody-cleaving enzymes for autoimmune and transplantation settings. Comparable by geography, size and immunomodulatory therapeutic focus.
Emerging players
- Calluna Pharma: Emerging biotech focused on inflammatory and autoimmune disease therapeutics. Relevant as an emerging peer developing novel immune tolerance and inflammation approaches.
- Anokion SA: Clinical-stage company developing antigen-specific immune tolerance therapies for autoimmune diseases. Closely aligned mechanistically with Toleranzia's tolerance-induction approach.
- Topas Therapeutics: Preclinical-stage biotech developing antigen-specific tolerance for autoimmune diseases. Directly comparable mechanism (tolerance induction) and pipeline scope.
- Cour Pharmaceuticals: Clinical-stage company developing antigen-specific tolerance therapies, including for autoimmune indications. Comparable modality and therapeutic area to Toleranzia.
- Kezar Life Sciences: Clinical-stage immunology biotech developing small-molecule therapies for autoimmune diseases. Comparable business model (clinical immunology biotech) and target indications.
- Immunic Therapeutics: Clinical-stage biotech developing oral immune modulators for chronic autoimmune and inflammatory diseases. Comparable size, stage and therapeutic focus.
Broad incumbents
- Flerie AB: Swedish public pharma/holding company that completed the merger with Toleranzia. Relevant as the surviving parent and adjacent investor/operator in Nordic pharma.
Regional players
- Alligator Bioscience AB: Swedish biotech developing antibody-based immunotherapies. Comparable by geography and immunology focus, though its pipeline skews toward oncology.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Toleranzia AB social profiles
Digital presenceToleranzia AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
Toleranzia AB leadership team
Management profileNumber of profiles
Profiles4 records
Toleranzia AB funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Toleranzia AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Toleranzia AB
What does Toleranzia AB do?
Toleranzia AB is a Swedish biotechnology company that develops a technology portfolio of therapeutic candidates aimed at treating autoimmune diseases through tolerance induction. The company's pipeline is focused on modulating the immune system to address underlying disease mechanisms rather than only managing symptoms. Following the August 2025 merger with Flerie AB, the operations were transferred to a newly created subsidiary that was renamed Bonsai Biotherapeutics AB.
Is Toleranzia AB a public or private company?
Toleranzia AB is a public company. It is classified as public and is currently acquired.
When was Toleranzia AB founded?
Toleranzia AB was founded in 2011. It employs 1 to 10 people.
Where is Toleranzia AB based?
Toleranzia AB is headquartered in Gothenburg, Sweden, in the Europe region.
Who are Toleranzia AB's main competitors?
Direct peers on record are BioInvent International AB and Hansa Biopharma AB. Emerging players are Calluna Pharma, Anokion SA, Topas Therapeutics, Cour Pharmaceuticals, Kezar Life Sciences and Immunic Therapeutics. Flerie AB is listed as a broad incumbent. Alligator Bioscience AB is listed as a regional player.
Does Toleranzia AB have an API?
No public API is recorded for Toleranzia AB.
What industry is Toleranzia AB in?
Toleranzia AB's product category is Biotechnology Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAAEAK, Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release). Its NAICS code is 541714 and its SIC code is 2834.